The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
CD4+ Count–Guided Interruption of Antiretroviral Treatment
Open accessAbstract
BACKGROUND: Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV). METHODS: We randomly assigned persons infected with HIV who had a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the viral suppression group) or the episodic use of antiretroviral therapy (the drug conservation group). Episodic use involved the deferral of therapy until the CD4+ count decreased to less than 250 per cubic millimeter and then the use of therapy until the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease. RESULTS: A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral suppression) were followed for an average of 16 months before the protocol was modified for the drug conservation group. At baseline, the median and nadir CD4+ counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per milliliter. Opportunistic disease or death from any cause occurred in 120 participants (3.3 events per 100 person-years) in the drug conservation group and 47 participants (1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardiovascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P=0.007) and 1.7 (95% CI, 1.1 to 2.5; P=0.009), respectively. Adjustment for the latest CD4+ count and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1). CONCLUSIONS: Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antiretroviral therapy, largely as a consequence of lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral therapy does not reduce the risk of adverse events that have been associated with antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Decay characteristics of HIV-1-infected compartments during combination therapy
Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., & Ho, D. D. (1997) · Nature · doi:10.1038/387188a0 · Cited by 1,880
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Qurishi, N., Kreuzberg, C., Lüchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T., Rockstroh, J. K., & Spengler, U. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14844-1 · Cited by 525
Crum, N. F., Riffenburgh, R. H., Wegner, S., Agan, B. K., Tasker, S. A., Spooner, K. M., Armstrong, A. W., Fraser, S., & Wallace, M. R. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000179459.31562.16 · Cited by 456
AIDS across Europe, 1994–98: the EuroSIDA study
Mocroft, A., Katlama, C., Johnson, A., Pradier, C., Antunes, F., Mulcahy, F., Chiesi, A., Phillips, A., Kirk, O., & Lundgren, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02504-6 · Cited by 453
Lewden, C. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh307 · Cited by 373
Latent reservoirs of HIV: Obstacles to the eradication of virus
Chun, T.-W., & Fauci, A. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.10958 · Cited by 342
Cardio- and cerebrovascular events in HIV-infected persons
(2004) · AIDS · doi:10.1097/00002030-200409030-00010 · Cited by 250
Ananworanich, J., Gayet-Ageron, A., Le Braz, M., Prasithsirikul, W., Chetchotisakd, P., Kiertiburanakul, S., Munsakul, W., Raksakulkarn, P., Tansuphasawasdikul, S., Sirivichayakul, S., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69153-8 · Cited by 240
Trends in Diseases Reported on U.S. Death Certificates That Mentioned HIV Infection, 1987–1999
Selik, R. M., Byers, R. H., & Dworkin, M. S. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200204010-00009 · Cited by 239
Danel, C., Moh, R., Minga, A., Anzian, A., Ba-Gomis, O., Kanga, C., Nzunetu, G., Gabillard, D., Rouet, F., Sorho, S., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68887-9 · Cited by 221
Liver toxicity caused by nevirapine
González de Requena, D., Núñez, M., Jiménez-Nácher, I., & Soriano, V. (2002) · AIDS · doi:10.1097/00002030-200201250-00020 · Cited by 176
The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy
The Antiretroviral Therapy Cohort Collaboration* (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.4.416 · Cited by 151
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
Mocroft, A., Soriano, V., Rockstroh, J. K., Reiss, P., Kirk, O., Wit, S. D., Gatell, J. M., Clotet, B., Phillips, A. N., & Lundgren, J. D. (2005) · AIDS · doi:10.1097/01.aids.0000194799.43799.ea · Cited by 133
Grade 4 Events Are as Important as AIDS Events in the Era of HAART
Reisler, R. B., Han, C., Burman, W. J., Tedaldi, E., & Neaton, J. D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200312010-00004 · Cited by 132
Structured Treatment Interruptions for the Management of HIV Infection
Lori, F., & Lisziewicz, J. (2001) · JAMA · doi:10.1001/jama.286.23.2981 · Cited by 108
Sample size calculation for complex clinical trials with survival endpoints
Shih, J. H. (1995) · Controlled Clinical Trials · doi:10.1016/s0197-2456(95)00132-8 · Cited by 94
Considerations in choice of a clinical endpoint for AIDS clinical trials
Neaton, J. D., Wentworth, D. N., Rhame, F. S., Hogan, C., Abrams, D. I., & Deyton, L. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131919 · Cited by 90
Crow, R. S., Prineas, R. J., Hannan, P. J., Grandits, G., & BLACKBURN, H. W. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00307-x · Cited by 68
Crow, R. S., Prineas, R. J., Jacobs, D. R., et al. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90420-7 · Cited by 53
Virologic and immunologic values allowing safe deferral of antiretroviral therapy
Phair, J., Mellors, J. W., Detels, R., Margolick, J. B., & Muñoz, Á. (2002) · AIDS · doi:10.1097/00002030-200212060-00011 · Cited by 46
To stop or not to stop: That is the question, but what is the answer?
Hogg, R. S., Havlir, D. V., Miller, V., & Montaner, J. S. G. (2002) · AIDS · doi:10.1097/00002030-200203290-00015 · Cited by 13
Cited by
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2283-2296
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1497170016
- Cited by
- 2,231
- References
- 33
- FWCI
- 91.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.